Potential markers of preeclampsia – a review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wilson JMG, Jungner G: Principles and Practice of Screening for Disease. Public Health Paper Number 34. 1968, Geneva: WHO
Audibert F: Screening for pre-eclampsia: the quest for the Holy Grail?. Lancet. 2005, 365: 1367-1369.
Redman CW, Sargent IL: Latest advances in understanding preeclampsia. Science. 2005, 308: 1592-1594.
Saito S, Shiozaki A, Nakashima A, Sakai M, Sasaki Y: The role of the immune system in preeclampsia. Mol Aspects Med. 2007, 28: 192-209.
Sargent IL, Borzychowski AM, Redman CW: Immunoregulation in normal pregnancy and pre-eclampsia: an overview. Reprod Biomed Online. 2006, 13: 680-686.
Catov JM, Ness RB, Kip KE, Olsen J: Risk of early or severe pre-eclampsia related to pre-existing conditions. Int J Epidemiol. 2007, 36: 412-419.
Wen SW, Chen XK, Rodger M, White RR, Yang Q, Smith GN, Sigal RJ, Perkins SL, Walker MC: Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol. 2008, 198: 45-47.
Bucher HC, Guyatt GH, Cook RJ, Hatala R, Cook DJ, Lang JD, Hunt D: Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. JAMA. 1996, 275: 1113-1117.
Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS: Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003, 101: 1319-1332.
Duley L, Henderson-Smart DJ, Meher S, King JF: Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007, CD004659-
Rumiris D, Purwosunu Y, Wibowo N, Farina A, Sekizawa A: Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status. Hypertens Pregnancy. 2006, 25: 241-253.
Hahn S, Gupta AK, Troeger C, Rusterholz C, Holzgreve W: Disturbances in placental immunology: ready for therapeutic interventions?. Springer Semin Immunopathol. 2006, 27: 477-493.
Huppertz B: The feto-maternal interface: setting the stage for potential immune interactions. Semin Immunopathol. 2007, 29: 83-94.
Jauniaux E, Poston L, Burton GJ: Placental-related diseases of pregnancy: Involvement of oxidative stress and implications in human evolution. Hum Reprod Update. 2006, 12: 747-755.
Hung TH, Skepper JN, Charnock-Jones DS, Burton GJ: Hypoxia-reoxygenation: a potent inducer of apoptotic changes in the human placenta and possible etiological factor in preeclampsia. Circ Res. 2002, 90: 1274-1281.
Soleymanlou N, Jurisica I, Nevo O, Ietta F, Zhang X, Zamudio S, Post M, Caniggia I: Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab. 2005, 90: 4299-4308.
Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003, 111: 649-658.
Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK: Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol. 1989, 161: 1200-1204.
Huppertz B: Placental origins of preeclampsia: challenging the current hypothesis. Hypertension. 2008, 51: 970-975.
Roberts JM, Hubel CA: The two stage model of preeclampsia: variations on the theme. Placenta. 2009, 30 (Suppl A): S32-S37.
Schutte JM, Schuitemaker NW, van RJ, Steegers EA: Substandard care in maternal mortality due to hypertensive disease in pregnancy in the Netherlands. BJOG. 2008, 115: 732-736.
von Dadelszen P, Magee LA, Roberts JM: Subclassification of preeclampsia. Hypertens Pregnancy. 2003, 22: 143-148.
Tjwa M, Luttun A, Autiero M, Carmeliet P: VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell Tissue Res. 2003, 314: 5-14.
Ahmed A, Li XF, Dunk C, Whittle MJ, Rushton DI, Rollason T: Colocalisation of vascular endothelial growth factor and its Flt-1 receptor in human placenta. Growth Factors. 1995, 12: 235-243.
Clark DE, Smith SK, Sharkey AM, Charnock-Jones DS: Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod. 1996, 11: 1090-1098.
Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS: Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol. 1998, 159: 459-467.
Khaliq A, Li XF, Shams M, Sisi P, Acevedo CA, Whittle MJ, Weich H, Ahmed A: Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors. 1996, 13: 243-50.
Crocker IP, Strachan BK, Lash GE, Cooper S, Warren AY, Baker PN: Vascular endothelial growth factor but not placental growth factor promotes trophoblast syncytialization in vitro. J Soc Gynecol Investig. 2001, 8: 341-346.
Desai J, Holt-Shore V, Torry RJ, Caudle MR, Torry DS: Signal transduction and biological function of placenta growth factor in primary human trophoblast. Biol Reprod. 1999, 60: 887-892.
Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS: Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta. 1997, 18: 657-665.
Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS: A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod. 1998, 59: 1540-1548.
Chaiworapongsa T, Romero R, Espinoza J, Bujold E, Mee KY, Goncalves LF, Gomez R, Edwin S: Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. Am J Obstet Gynecol. 2004, 190: 1541-1547.
Chung JY, Song Y, Wang Y, Magness RR, Zheng J: Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2004, 89: 2484-2490.
Levine RJ, Karumanchi SA: Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol. 2005, 48: 372-386.
Torry DS, Wang HS, Wang TH, Caudle MR, Torry RJ: Preeclampsia is associated with reduced serum levels of placenta growth factor. Am J Obstet Gynecol. 1998, 179: 1539-1544.
Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A, Schaaps JP, Cabrol D, Frankenne F, Foidart JM: Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab. 2003, 88: 5555-5563.
Robinson CJ, Johnson DD, Chang EY, Armstrong DM, Wang W: Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am J Obstet Gynecol. 2006, 195: 255-259.
Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden-Lindeberg S, Olovsson M: Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol. 2007, 109: 1368-1374.
Stepan H, Kramer T, Faber R: Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J Clin Endocrinol Metab. 2007, 92: 2831-2834.
Ahmad S, Ahmed A: Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004, 95: 884-891.
Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Goncalves L, Gomez R, Edwin S, Mazor M: Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med. 2005, 17: 3-18.
Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004, 350: 672-683.
Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK: Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol. 2003, 101: 1266-1274.
Thadhani R, Mutter WP, Wolf M, Levine RJ, Taylor RN, Sukhatme VP, Ecker J, Karumanchi SA: First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab. 2004, 89: 770-775.
Tidwell SC, Ho HN, Chiu WH, Torry RJ, Torry DS: Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia. Am J Obstet Gynecol. 2001, 184: 1267-1272.
Tjoa ML, van Vugt JM, Mulders MA, Schutgens RB, Oudejans CB, van WI: Plasma placenta growth factor levels in midtrimester pregnancies. Obstet Gynecol. 2001, 98: 600-607.
Romero R, Nien JK, Espinoza J, Todem D, Fu W, Chung H, Kusanovic JP, Gotsch F, Erez O, Mazaki-Tovi S, Gomez R, Edwin S, Chaiworapongsa T, Levine RJ, Karumanchi SA: A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008, 21: 9-23.
Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE: Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol. 2007, 197: 244-248.
Aggarwal PK, Jain V, Sakhuja V, Karumanchi SA, Jha V: Low urinary placental growth factor is a marker of pre-eclampsia. Kidney Int. 2006, 69: 621-624.
Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA: Urinary placental growth factor and risk of preeclampsia. JAMA. 2005, 293: 77-85.
Wathen KA, Tuutti E, Stenman UH, Alfthan H, Halmesmaki E, Finne P, Ylikorkala O, Vuorela P: Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab. 2006, 91: 180-184.
Stepan H, Unversucht A, Wessel N, Faber R: Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007, 49: 818-824.
Chaiworapongsa T, Romero R, Gotsch F, Espinoza J, Nien JK, Goncalves L, Edwin S, Kim YM, Erez O, Kusanovic JP, Pineles BL, Papp Z, Hassan S: Low maternal concentrations of soluble vascular endothelial growth factor receptor-2 in preeclampsia and small for gestational age. J Matern Fetal Neonatal Med. 2008, 21: 41-52.
Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M: Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. J Biol Chem. 1992, 267: 19027-19030.
St-Jacques S, Forte M, Lye SJ, Letarte M: Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod. 1994, 51: 405-413.
Duff SE, Li C, Garland JM, Kumar S: CD105 is important for angiogenesis: evidence and potential applications. FASEB J. 2003, 17: 984-992.
Toporsian M, Gros R, Kabir MG, Vera S, Govindaraju K, Eidelman DH, Husain M, Letarte M: A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005, 96: 684-692.
Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA: Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006, 12: 642-649.
Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A: Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta. 2008, 29: 555-563.
Salahuddin S, Lee Y, Vadnais M, Sachs BP, Karumanchi SA, Lim KH: Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 2007, 197: 28-6.
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA: Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006, 355: 992-1005.
Rana S, Karumanchi SA, Levine RJ, Venkatesha S, Rauh-Hain JA, Tamez H, Thadhani R: Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007, 50: 137-142.
Robinson CJ, Johnson DD: Soluble endoglin as a second-trimester marker for preeclampsia. Am J Obstet Gynecol. 2007, 197: 174-175.
Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R: Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol. 2008, 198: 175-176.
Erez O, Romero R, Espinoza J, Fu W, Todem D, Kusanovic JP, Gotsch F, Edwin S, Nien JK, Chaiworapongsa T, Mittal P, Mazaki-Tovi S, Than NG, Gomez R, Hassan SS: The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med. 2008, 21: 279-287.
Polgar J, Matuskova J, Wagner DD: The P-selectin, tissue factor, coagulation triad. J Thromb Haemost. 2005, 3: 1590-1596.
Dunlop LC, Skinner MP, Bendall LJ, Favaloro EJ, Castaldi PA, Gorman JJ, Gamble JR, Vadas MA, Berndt MC: Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med. 1992, 175: 1147-1150.
Holthe MR, Staff AC, Berge LN, Lyberg T: Different levels of platelet activation in preeclamptic, normotensive pregnant, and nonpregnant women. Am J Obstet Gynecol. 2004, 190: 1128-1134.
Konijnenberg A, Stokkers EW, Post van der JA, Schaap MC, Boer K, Bleker OP, Sturk A: Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol. 1997, 176: 461-469.
Yoneyama Y, Suzuki S, Sawa R, Kiyokawa Y, Power GG, Araki T: Plasma adenosine levels and P-selectin expression on platelets in preeclampsia. Obstet Gynecol. 2001, 97: 366-370.
Bretelle F, Sabatier F, Desprez D, Camoin L, Grunebaum L, Combes V, D'Ercole C, gnat-George F: Circulating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost. 2003, 89: 486-492.
Lok CA, Nieuwland R, Sturk A, Hau CM, Boer K, Vanbavel E, Vanderpost JA: Microparticle-associated P-selectin reflects platelet activation in preeclampsia. Platelets. 2007, 18: 68-72.
Aksoy H, Kumtepe Y, Akcay F, Yildirim AK: Correlation of P-selectin and lipoprotein(a), and other lipid parameters in preeclampsia. Clin Exp Med. 2002, 2: 39-43.
Chaiworapongsa T, Romero R, Yoshimatsu J, Espinoza J, Kim YM, Park K, Kalache K, Edwin S, Bujold E, Gomez R: Soluble adhesion molecule profile in normal pregnancy and pre-eclampsia. J Matern Fetal Neonatal Med. 2002, 12: 19-27.
Halim A, Kanayama N, el ME, Nakashima A, Bhuiyan AB, Khatun S, Terao T: Plasma P selectin (GMP-140) and glycocalicin are elevated in preeclampsia and eclampsia: their significances. Am J Obstet Gynecol. 1996, 174: 272-277.
Heyl W, Handt S, Reister F, Gehlen J, Schroder W, Mittermayer C, Rath W: Elevated soluble adhesion molecules in women with pre-eclampsia. Do cytokines like tumour necrosis factor-alpha and interleukin-1beta cause endothelial activation. Eur J Obstet Gynecol Reprod Biol. 1999, 86: 35-41.
Banzola I, Farina A, Concu M, Sekizawa A, Purwosunu Y, Strada I, Arcelli D, Simonazzi G, Caramelli E, Rizzo N: Performance of a panel of maternal serum markers in predicting preeclampsia at 11–15 weeks' gestation. Prenat Diagn. 2007, 27: 1005-1010.
Bosio PM, Cannon S, McKenna PJ, O'Herlihy C, Conroy R, Brady H: Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia. BJOG. 2001, 108: 709-715.
Chavarria ME, Lara-Gonzalez L, Garcia-Paleta Y, Vital-Reyes VS, Reyes A: Adhesion molecules changes at 20 gestation weeks in pregnancies complicated by preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2008, 137: 157-164.
Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, Wainscoat JS: Presence of fetal DNA in maternal plasma and serum. Lancet. 1997, 350: 485-487.
Hromadnikova I, Vechetova L, Vesela K, Benesova B, Doucha J, Kulovany E, Vlk R: Non-invasive fetal RHD exon 7 and exon 10 genotyping using real-time PCR testing of fetal DNA in maternal plasma. Fetal Diagn Ther. 2005, 20: 275-280.
Finning K, Martin P, Daniels G: A clinical service in the UK to predict fetal Rh (Rhesus) D blood group using free fetal DNA in maternal plasma. Ann N Y Acad Sci. 2004, 1022: 119-123.
Li Y, Holzgreve W, Hahn S: Size fractionation of cell-free DNA in maternal plasma and its application in noninvasive detection of fetal single gene point mutations. Methods Mol Biol. 2008, 444: 239-251.
Sekizawa A, Jimbo M, Saito H, Iwasaki M, Matsuoka R, Okai T, Farina A: Cell-free fetal DNA in the plasma of pregnant women with severe fetal growth restriction. Am J Obstet Gynecol. 2003, 188: 480-484.
Zhong XY, Holzgreve W, Li JC, Aydinli K, Hahn S: High levels of fetal erythroblasts and fetal extracellular DNA in the peripheral blood of a pregnant woman with idiopathic polyhydramnios: case report. Prenat Diagn. 2000, 20: 838-841.
Wataganara T, LeShane ES, Farina A, Messerlian GM, Lee T, Canick JA, Bianchi DW: Maternal serum cell-free fetal DNA levels are increased in cases of trisomy 13 but not trisomy 18. Hum Genet. 2003, 112: 204-208.
Farina A, LeShane ES, Lambert-Messerlian GM, Canick JA, Lee T, Neveux LM, Palomaki GE, Bianchi DW: Evaluation of cell-free fetal DNA as a second-trimester maternal serum marker of Down syndrome pregnancy. Clin Chem. 2003, 49: 239-242.
Vodicka R, Vrtel R, Dusek L, Prochazka M, Schneiderova E, Vrbicka D, Krejcirikova E, Dhaifalah I, Santava A, Santavy J: Refined fluorescent STR quantification of cell-free fetal DNA during pregnancy in physiological and Down syndrome fetuses. Prenat Diagn. 2008, 28: 425-433.
Farina A, LeShane ES, Romero R, Gomez R, Chaiworapongsa T, Rizzo N, Bianchi DW: High levels of fetal cell-free DNA in maternal serum: a risk factor for spontaneous preterm delivery. Am J Obstet Gynecol. 2005, 193: 421-425.
Lo YM, Leung TN, Tein MS, Sargent IL, Zhang J, Lau TK, Haines CJ, Redman CW: Quantitative abnormalities of fetal DNA in maternal serum in preeclampsia. Clin Chem. 1999, 45: 184-188.
Zhong XY, Holzgreve W, Hahn S: The levels of circulatory cell free fetal DNA in maternal plasma are elevated prior to the onset of preeclampsia. Hypertens Pregnancy. 2002, 21: 77-83.
Levine RJ, Qian C, LeShane ES, Yu KF, England LJ, Schisterman EF, Wataganara T, Romero R, Bianchi DW: Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol. 2004, 190: 707-713.
Zimmermann BG, Maddocks DG, Avent ND: Quantification of circulatory fetal DNA in the plasma of pregnant women. Methods Mol Biol. 2008, 444: 219-229.
Farina A, Sekizawa A, Iwasaki M, Matsuoka R, Ichizuka K, Okai T: Total cell-free DNA (beta-globin gene) distribution in maternal plasma at the second trimester: a new prospective for preeclampsia screening. Prenat Diagn. 2004, 24: 722-726.
Sekizawa A, Farina A, Koide K, Iwasaki M, Honma S, Ichizuka K, Saito H, Okai T: beta-globin DNA in maternal plasma as a molecular marker of pre-eclampsia. Prenat Diagn. 2004, 24: 697-700.
Swinkels DW, de Kok JB, Hendriks JC, Wiegerinck E, Zusterzeel PL, Steegers EA: Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome as a complication of preeclampsia in pregnant women increases the amount of cell-free fetal and maternal DNA in maternal plasma and serum. Clin Chem. 2002, 48: 650-653.
Chim SS, Tong YK, Chiu RW, Lau TK, Leung TN, Chan LY, Oudejans CB, Ding C, Lo YM: Detection of the placental epigenetic signature of the maspin gene in maternal plasma. Proc Natl Acad Sci USA. 2005, 102: 14753-14758.
Chan KC, Ding C, Gerovassili A, Yeung SW, Chiu RW, Leung TN, Lau TK, Chim SS, Chung GT, Nicolaides KH, Lo YM: Hypermethylated RASSF1A in maternal plasma: A universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis. Clin Chem. 2006, 52: 2211-2218.
Tsui DW, Chan KC, Chim SS, Chan LW, Leung TY, Lau TK, Lo YM, Chiu RW: Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia. Prenat Diagn. 2007, 27: 1212-1218.
Diesch CH, Holzgreve W, Hahn S, Zhong XY: Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia. Prenat Diagn. 2006, 26: 1267-1270.
Cho C, Turner L, Primakoff P, Myles DG: Genomic organization of the mouse fertilin beta gene that encodes an ADAM family protein active in sperm-egg fusion. Dev Genet. 1997, 20: 320-328.
White JM: ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol. 2003, 15: 598-606.
Yang P, Baker KA, Hagg T: A disintegrin and metalloprotease 21 (ADAM21) is associated with neurogenesis and axonal growth in developing and adult rodent CNS. J Comp Neurol. 2005, 490: 163-179.
Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM: A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem. 1998, 273: 157-166.
Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, Pedersen BN, Wewer UM: ADAM 12 as a first-trimester maternal serum marker in screening for Down syndrome. Prenat Diagn. 2006, 26: 973-979.
Laigaard J, Christiansen M, Frohlich C, Pedersen BN, Ottesen B, Wewer UM: The level of ADAM12-S in maternal serum is an early first-trimester marker of fetal trisomy 18. Prenat Diagn. 2005, 25: 45-46.
Laigaard J, Sorensen T, Frohlich C, Pedersen BN, Christiansen M, Schiott K, Uldbjerg N, Albrechtsen R, Clausen HV, Ottesen B, Wewer UM: ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn. 2003, 23: 1086-1091.
Spencer K, Cowans NJ: ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy. J Matern Fetal Neonatal Med. 2007, 20: 645-650.
Spencer K, Cowans NJ, Stamatopoulou A: Maternal serum ADAM12s as a marker of rare aneuploidies in the first or second trimester of pregnancy. Prenat Diagn. 2007, 27: 1233-1237.
Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann KR, Sundberg K, Shalmi AC, Tabor A, Norgaard-Pedersen B, Ottesen B, Christiansen M, Wewer UM: Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol. 2005, 106: 144-149.
Spencer K, Cowans NJ, Stamatopoulou A: ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat Diagn. 2008, 28: 212-216.
Poon LC, Chelemen T, Granvillano O, Pandeva I, Nicolaides KH: First-trimester maternal serum a disintegrin and metalloprotease 12 (ADAM12) and adverse pregnancy outcome. Obstet Gynecol. 2008, 112: 1082-1090.
Bohn H, Kraus W, Winckler W: Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17). Oncodev Biol Med. 1983, 4: 343-350.
Visegrady B, Than NG, Kilar F, Sumegi B, Than GN, Bohn H: Homology modelling and molecular dynamics studies of human placental tissue protein 13 (galectin-13). Protein Eng. 2001, 14: 875-880.
Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, Janaky T, Boronkai A, Kliman H, Meiri H, Bohn H, Than GN, Sumegi B: Functional analyses of placental protein 13/galectin-13. Eur J Biochem. 2004, 271: 1065-1078.
Than NG, Sumegi B, Than GN, Berente Z, Bohn H: Isolation and sequence analysis of a cDNA encoding human placental tissue protein 13 (PP13), a new lysophospholipase, homologue of human eosinophil Charcot-Leyden Crystal protein. Placenta. 1999, 20: 703-710.
Sekizawa A, Purwosunu Y, Yoshimura S, Nakamura M, Shimizu H, Okai T, Rizzo N, Farina A: PP13 mRNA expression in trophoblasts from preeclamptic placentas. Reprod Sci. 2009, 16: 408-413.
Huppertz B, Sammar M, Chefetz I, Neumaier-Wagner P, Bartz C, Meiri H: Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn Ther. 2008, 24: 230-236.
Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, Cuckle H, Wolf M: First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007, 197: 35-37.
Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H: First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007, 29: 128-134.
Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, Mandel S, Rabinovitch L, Paltieli Y, Admon A, Gonen R: Placental protein 13 (PP-13): effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta. 2004, 25: 608-622.
Khalil A, Cowans NJ, Spencer K, Goichman S, Meiri H, Harrington K: First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk. Prenat Diagn. 2009,
Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, Edwin S, Chefetz I, Gomez R, Nien JK, Sammar M, Pineles B, Hassan SS, Meiri H, Tal Y, Kuhnreich I, Papp Z, Cuckle HS: First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008, 199 (2): 122-
Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, Tal J, Cuckle HS: A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol. 2006, 27: 13-17.
Spencer K, Cowans NJ, Chefetz I, Tal J, Kuhnreich I, Meiri H: Second-trimester uterine artery Doppler pulsatility index and maternal serum PP13 as markers of pre-eclampsia. Prenat Diagn. 2007, 27: 258-263.
Souza DG, Soares AC, Pinho V, Torloni H, Reis LF, Teixeira MM, Dias AA: Increased mortality and inflammation in tumor necrosis factor-stimulated gene-14 transgenic mice after ischemia and reperfusion injury. Am J Pathol. 2002, 160: 1755-1765.
Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M: Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem. 1992, 267: 22190-22197.
Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A: Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 1994, 84: 3483-3493.
Inforzato A, Peri G, Doni A, Garlanda C, Mantovani A, Bastone A, Carpentieri A, Amoresano A, Pucci P, Roos A, Daha MR, Vincenti S, Gallo G, Carminati P, De SR, Salvatori G: Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. Biochemistry. 2006, 45: 11540-11551.
Popovici RM, Krause MS, Jauckus J, Germeyer A, Brum IS, Garlanda C, Strowitzki T, von WM: The long pentraxin PTX3 in human endometrium: regulation by steroids and trophoblast products. Endocrinology. 2008, 149: 1136-1143.
Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Vago L, Pardi G, Mantovani A: Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006, 194: 1347-1353.
Rovere-Querini P, Antonacci S, Dell'Antonio G, Angeli A, Almirante G, Cin ED, Valsecchi L, Lanzani C, Sabbadini MG, Doglioni C, Manfredi AA, Castiglioni MT: Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006, 108: 148-155.
Lawrence JB, Bale LK, Haddad TC, Clarkson JT, Conover CA: Characterization and partial purification of the insulin-like growth factor (IGF)-dependent IGF binding protein-4-specific protease from human fibroblast conditioned media. Growth Horm IGF Res. 1999, 9: 25-34.
Chen BK, Overgaard MT, Bale LK, Resch ZT, Christiansen M, Oxvig C, Conover CA: Molecular regulation of the IGF-binding protein-4 protease system in human fibroblasts: identification of a novel inducible inhibitor. Endocrinology. 2002, 143: 1199-1205.
Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR, Conover CA: The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci USA. 1999, 96: 3149-3153.
Chelius D, Conover CA, Baldwin MA, Spencer EM: Characterization of the enzymatic specificity of the IGF-dependent insulin-like growth factor binding protein-4 (IGFBP-4) protease. Growth Horm IGF Res. 2000, 10: 360-366.
Jadlowiec J, Dongell D, Smith J, Conover C, Campbell P: Pregnancy-associated plasma protein-a is involved in matrix mineralization of human adult mesenchymal stem cells and angiogenesis in the chick chorioallontoic membrane. Endocrinology. 2005, 146: 3765-3772.
Miller BS, Bronk JT, Nishiyama T, Yamagiwa H, Srivastava A, Bolander ME, Conover CA: Pregnancy associated plasma protein-A is necessary for expeditious fracture healing in mice. J Endocrinol. 2007, 192: 505-513.
Cowans NJ, Spencer K: First-trimester ADAM12 and PAPP-A as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn. 2007, 27: 264-271.
Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, Hankins G, Berkowitz RL, Merkatz I, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Vidaver J, D'Alton ME: First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004, 191: 1446-1451.
Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, Silver R, Pergament E, Platt LD, Filkins K, Johnson A, Mahoney M, Hogge WA, Wilson RD, Mohide P, Hershey D, Wapner R: Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004, 191: 1452-1458.
Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH: First trimester maternal serum free beta human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG. 2000, 107: 1265-1270.
Smith GC, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM: Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002, 87: 1762-1767.
Spencer K, Cowans NJ, Chefetz I, Tal J, Meiri H: First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol. 2007, 29: 128-134.
Spencer K, Cowans NJ, Nicolaides KH: Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn. 2008, 28: 7-10.
Spencer K, Cowans NJ, Molina F, Kagan KO, Nicolaides KH: First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol. 2008, 31: 147-152.
Tul N, Pusenjak S, Osredkar J, Spencer K, Novak-Antolic Z: Predicting complications of pregnancy with first-trimester maternal serum free-betahCG, PAPP-A and inhibin-A. Prenat Diagn. 2003, 23: 990-996.
Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, Orr-Urtreger A: Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. Prenat Diagn. 2002, 22: 778-782.
Toop K, Klopper A: Concentration of pregnancy-associated plasma protein A (PAPP-A) in patients with pre-eclamptic toxaemia. Placenta Suppl. 1981, 3: 167-173.
Preiss J, Handler P: Enzymatic synthesis of nicotinamide mononucleotide. J Biol Chem. 1957, 225: 759-770.
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005, 307: 426-430.
Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernandez-Real JM: Serum visfatin increases with progressive beta-cell deterioration. Diabetes. 2006, 55: 2871-2875.
Pagano C, Pilon C, Olivieri M, Mason P, Fabris R, Serra R, Milan G, Rossato M, Federspil G, Vettor R: Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006, 91: 3165-3170.
Fasshauer M, Bluher M, Stumvoll M, Tonessen P, Faber R, Stepan H: Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol (Oxf). 2007, 66: 434-439.
Krzyzanowska K, Krugluger W, Mittermayer F, Rahman R, Haider D, Shnawa N, Schernthaner G: Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond). 2006, 110: 605-609.
Hu W, Wang Z, Wang H, Huang H, Dong M: Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynecol Scand. 2008, 87: 413-418.
Fasshauer M, Waldeyer T, Seeger J, Schrey S, Ebert T, Kratzsch J, Lossner U, Bluher M, Stumvoll M, Faber R, Stepan H: Serum levels of the adipokine visfatin are increased in preeclampsia. Clin Endocrinol (Oxf). 2007
Kitamura K, Kangawa K, Kawamoto M, Ichiki Y, Nakamura S, Matsuo H, Eto T: Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993, 192: 553-560.
Hinson JP, Kapas S, Smith DM: Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev. 2000, 21: 138-167.
Hippenstiel S, Witzenrath M, Schmeck B, Hocke A, Krisp M, Krull M, Seybold J, Seeger W, Rascher W, Schutte H, Suttorp N: Adrenomedullin reduces endothelial hyperpermeability. Circ Res. 2002, 91: 618-625.
Kato J, Tsuruda T, Kita T, Kitamura K, Eto T: Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol. 2005, 25: 2480-2487.
Senna AA, Zedan M, bd El Salam GE, El Mashad AI: Study of plasma adrenomedullin level in normal pregnancy and preclampsia. Medscape J Med. 2008, 10: 29-
Gratton RJ, Gluszynski M, Mazzuca DM, Nygard K, Han VK: Adrenomedullin messenger ribonucleic acid expression in the placentae of normal and preeclamptic pregnancies. J Clin Endocrinol Metab. 2003, 88: 6048-6055.
Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jupner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC: Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999, 103: 945-952.
Herse F, Staff AC, Hering L, Muller DN, Luft FC, Dechend R: AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. J Mol Med. 2008, 86: 697-703.
Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, Stepan H: Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension. 2005, 46: 1275-1279.
Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, Kintscher U, Rudolph B, Hoebeke J, Eckert D, Mazak I, Plehm R, Schonemann C, Unger T, Budde K, Neumayer HH, Luft FC, Wallukat G: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005, 352: 558-569.
Zhou CC, Ahmad S, Mi T, Abbasi S, Xia L, Day MC, Ramin SM, Ahmed A, Kellems RE, Xia Y: Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension. 2008, 51: 1010-1019.
Herse F, Verlohren S, Wenzel K, Pape J, Muller DN, Modrow S, Wallukat G, Luft FC, Redman CW, Dechend R: Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension. 2009, 53: 393-398.
Chien PF, Arnott N, Gordon A, Owen P, Khan KS: How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. BJOG. 2000, 107: 196-208.
Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, Zwinderman AH, Robson SC, Bindels PJ, Kleijnen J, Khan KS: Use of uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction: a systematic review and bivariable meta-analysis. CMAJ. 2008, 178: 701-711.
Barton JR, Sibai BM: Prediction and prevention of recurrent preeclampsia. Obstet Gynecol. 2008, 112: 359-372.
Savvidou MD, Noori M, Anderson JM, Hingorani AD, Nicolaides KH: Maternal endothelial function and serum concentrations of placental growth factor and soluble endoglin in women with abnormal placentation. Ultrasound Obstet Gynecol. 2008, 32: 871-876.
Enquobahrie DA, Meller M, Rice K, Psaty BM, Siscovick DS, Williams MA: Differential placental gene expression in preeclampsia. Am J Obstet Gynecol. 2008, 199 (5): e1-11.
Gack S, Marme A, Marme F, Wrobel G, Vonderstrass B, Bastert G, Lichter P, Angel P, Schorpp-Kistner M: Preeclampsia: increased expression of soluble ADAM 12. J Mol Med. 2005, 83: 887-896.
Reimer T, Koczan D, Gerber B, Richter D, Thiesen HJ, Friese K: Microarray analysis of differentially expressed genes in placental tissue of pre-eclampsia: up-regulation of obesity-related genes. Mol Hum Reprod. 2002, 8: 674-680.
Zhou R, Zhu Q, Wang Y, Ren Y, Zhang L, Zhou Y: Genomewide oligonucleotide microarray analysis on placentae of pre-eclamptic pregnancies. Gynecol Obstet Invest. 2006, 62: 108-114.
Hansson SR, Chen Y, Brodszki J, Chen M, Hernandez-Andrade E, Inman JM, Kozhich OA, Larsson I, Marsal K, Medstrand P, Xiang CC, Brownstein MJ: Gene expression profiling of human placentas from preeclamptic and normotensive pregnancies. Mol Hum Reprod. 2006, 12: 169-179.
Heikkila A, Tuomisto T, Hakkinen SK, Keski-Nisula L, Heinonen S, Yla-Herttuala S: Tumor suppressor and growth regulatory genes are overexpressed in severe early-onset preeclampsia–an array study on case-specific human preeclamptic placental tissue. Acta Obstet Gynecol Scand. 2005, 84: 679-689.
Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, Hering L, Muller DN, Luft FC, Staff AC: Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. Hypertension. 2007, 49: 604-611.
Pang ZJ, Xing FQ: Comparative profiling of metabolism-related gene expression in pre-eclamptic and normal pregnancies. Arch Gynecol Obstet. 2004, 269: 91-95.
Tsui NB, Lo YM: A microarray approach for systematic identification of placental-derived RNA markers in maternal plasma. Methods Mol Biol. 2008, 444: 275-289.
Ng EK, Tsui NB, Lau TK, Leung TN, Chiu RW, Panesar NS, Lit LC, Chan KW, Lo YM: mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci USA. 2003, 100: 4748-4753.
Ng EK, El-Sheikhah A, Chiu RW, Chan KC, Hogg M, Bindra R, Leung TN, Lau TK, Nicolaides KH, Lo YM: Evaluation of human chorionic gonadotropin beta-subunit mRNA concentrations in maternal serum in aneuploid pregnancies: a feasibility study. Clin Chem. 2004, 50: 1055-1057.
Tsui NB, Chim SS, Chiu RW, Lau TK, Ng EK, Leung TN, Tong YK, Chan KC, Lo YM: Systematic micro-array based identification of placental mRNA in maternal plasma: towards non-invasive prenatal gene expression profiling. J Med Genet. 2004, 41: 461-467.
Ng EK, Leung TN, Tsui NB, Lau TK, Panesar NS, Chiu RW, Lo YM: The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin Chem. 2003, 49: 727-731.
Herzog A, Kuntz S, Daniel H, Wenzel U: Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004, 109: 220-229.
Reddy CS, Holzgreve W, Hahn S: Detection of new screening markers for fetal aneuploidies in maternal plasma: a proteomic approach. Methods Mol Biol. 2008, 444: 311-326.
Cho SY, Lee EY, Kim HY, Kang MJ, Lee HJ, Kim H, Paik YK: Protein profiling of human plasma samples by two-dimensional electrophoresis. Methods Mol Biol. 2008, 428: 57-75.
Gluckmann M, Fella K, Waidelich D, Merkel D, Kruft V, Kramer PJ, Walter Y, Hellmann J, Karas M, Kroger M: Prevalidation of potential protein biomarkers in toxicology using iTRAQ reagent technology. Proteomics. 2007, 7: 1564-1574.
Abdi F, Quinn JF, Jankovic J, McIntosh M, Leverenz JB, Peskind E, Nixon R, Nutt J, Chung K, Zabetian C, Samii A, Lin M, Hattan S, Pan C, Wang Y, Jin J, Zhu D, Li GJ, Liu Y, Waichunas D, Montine TJ, Zhang J: Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006, 9: 293-348.
Desouza LV, Grigull J, Ghanny S, Dube V, Romaschin AD, Colgan TJ, Siu KW: Endometrial carcinoma biomarker discovery and verification using differentially tagged clinical samples with multidimensional liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics. 2007, 6: 1170-1182.
Ralhan R, Desouza LV, Matta A, Chandra TS, Ghanny S, Datta GS, Bahadur S, Siu KW: Discovery and verification of head-and-neck cancer biomarkers by differential protein expression analysis using iTRAQ labeling, multidimensional liquid chromatography, and tandem mass spectrometry. Mol Cell Proteomics. 2008, 7: 1162-1173.
Heazell AE, Brown M, Dunn WB, Worton SA, Crocker IP, Baker PN, Kell DB: Analysis of the metabolic footprint and tissue metabolome of placental villous explants cultured at different oxygen tensions reveals novel redox biomarkers. Placenta. 2008, 29: 691-698.